Video

Dr. Rini on the Results From His Axitinib and Sorafenib Trial

Author(s):

Brian I. Rini, MD

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Results From His Axitinib and Sorafenib Trial

Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic in Ohio, explains the results of the AXIS 1032 phase III trial comparing axitinib to sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).

Related Videos
Fred Saad, CQ, MD, FRCS, FCAHS
Eric Kumar Singhi, MD
Seth Wander, MD, PhD
Lillian L. Siu, MD, FRCPC
Marc Machaalani, MD
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD
Related Content
FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Vijayakrishna Gadi, MD, PhD, of University of Illinois College of Medicine Chicago
October 1st 2024

HER2-Directed ADCs Spread Like Wildfire Across the Spectrum of Solid Malignancies

Neal Shore, MD, FACS
January 26th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

RCC: stock.adobe.com
October 1st 2024

Fecal Microbiota Transplantation Boosts Response to Pembrolizumab Plus Axitinib in mRCC

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.
September 28th 2024

The OncFive: Top Oncology Articles for the Week 9/22